MedTrace Logo

Tissue-Engineered Construct Based on Amniotic Membrane and Calcium Alginate for Cesarean Section Wound Healing

NCT07241013 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-11-21

No results posted yet for this study

Summary

This clinical trial aims to evaluate the safety and efficacy of an experimental tissue-engineered construct (TEC) based on amniotic membrane and calcium alginate for promoting epithelialization and improving scar quality in patients after cesarean section. The study will assess both biological and clinical indicators of wound healing, including cytokine dynamics (IL-6, IL-10), ultrasound characteristics, and patient-reported outcomes.

Conditions

  • Skin Wound Healing After Cesarean Section
  • Cesarean Section Scar Healing

Interventions

DEVICE

Tissue-engineered construct based on amniotic membrane and calcium alginate (TEC)

Application of a bioresorbable tissue-engineered construct (based on amniotic membrane and calcium alginate) on the postoperative skin incision site to promote epithelialization and improve scar healing.

Sponsors & Collaborators

  • Center for Perinatology and Pediatric Surgery, Almaty, Kazakhstan

    collaborator UNKNOWN

  • Zhalyn Scientific and Technical Production Center, Almaty, Kazakhstan

    collaborator UNKNOWN

  • Asfendiyarov Kazakh National Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-30
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07241013 on ClinicalTrials.gov